Blog
RSS FeedPosted by Michael Wonder on 12 Jul 2023
Lorlatinib for the treatment of adults with advanced ALK positive non-small-cell lung cancer
12 July 2023 - NICE has published final evidence-based recommendations on the use of lorlatinib (Lorviqua) for the treatment of ...
Posted by Michael Wonder on 05 Jul 2023
Rimegepant sulphate for the prevention of migraine
5 July 2023 - NICE has published final evidence-based recommendations on the use of rimegepant sulphate (Vydura) for the prevention ...
Posted by Michael Wonder on 05 Jul 2023
Olaparib for the maintenance treatment of adults with relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after two or more courses of platinum-based chemotherapy
5 July 2023 - NICE has published final evidence-based recommendations on the use of olaparib (Lynparza) for the maintenance treatment ...
Posted by Michael Wonder on 29 Jun 2023
Secukinumab for the treatment of patients with moderate to severe hidradenitis suppurativa
29 June 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 28 Jun 2023
Deucravacitinib for the treatment of patients with moderate to severe plaque psoriasis
28 June 2023 - NICE has published final evidence-based recommendations on the use of deucravacitinib for the treatment of adults ...
Posted by Michael Wonder on 27 Jun 2023
NICE launches public consultation on updates to health technology evaluations manual
27 June 2023 - A public consultation on updates to NICE’s health technology evaluations manual is now open. ...
Posted by Michael Wonder on 27 Jun 2023
More evidence needed to recommend type 2 diabetes treatment tirzepatide
27 June 2023 - More evidence is needed on the clinical and cost effectiveness of a new treatment option for patients ...
Posted by Michael Wonder on 27 Jun 2023
Olaparib in combination with bevacizumab for the maintenance treatment of adults with advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
27 June 2023 - The Department of Health and Social Care has asked the NICE to review its guidance on ...
Posted by Michael Wonder on 22 Jun 2023
Upadacitinib monohydrate for the treatment of patients with previously treated moderately to severely active Crohn’s disease
21 June 2023 - NICE has published final evidence-based recommendations on the use of upadacitinib monohydrate (Rinvoq) for the treatment ...
Posted by Michael Wonder on 21 Jun 2023
Darolutamide in combination with androgen deprivation therapy and docetaxel for the treatment of patients with hormone-sensitive metastatic prostate cancer
21 June 2023 - NICE has published final evidence-based recommendations on the use of darolutamide (Nubeqa) in combination with androgen ...
Posted by Michael Wonder on 20 Jun 2023
Cemiplimab for the treatment of patients with recurrent or metastatic cervical cancer
20 June 2023 - NICE is unable to make a recommendation on the use of cemiplimab (Libtayo) for the treatment of ...
Posted by Michael Wonder on 14 Jun 2023
Tixagevimab and cilgavimab for the prevention of COVID-19 disease
14 June 2023 - NICE has published final evidence-based recommendations on the use of tixagevimab and cilgavimab (Evusheld) for the ...
Posted by Michael Wonder on 14 Jun 2023
Dabrafenib mesylate and trametinib dimethyl sulphoxide for the treatment of patients with advanced BRAF V600 mutation positive non-small-cell lung cancer
14 June 2023 - NICE has published final evidence-based recommendations on the use of dabrafenib mesylate (Tafinlar) and trametinib dimethyl ...
Posted by Michael Wonder on 07 Jun 2023
Bulevirtide acetate for the treatment of adults with chronic hepatitis D (final guidance)
7 June 2023 - NICE has published final evidence based recommendations on the use of bulevirtide (Hepcludex) for the treatment ...
Posted by Michael Wonder on 07 Jun 2023
New drugs pilot to tackle obesity and cut NHS waiting lists
7 June 2023 - More people living with obesity will have access to the newest and most effective obesity drugs to ...